OOIR: Observatory of International Research

Papers

(The TQCC of Oncogenesis is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
MYB oncoproteins: emerging players and potential therapeutic targets in human cancer	101
Exosomes and cancer - Diagnostic and prognostic biomarkers and therapeutic vehicle	99
Single-cell RNA sequencing reveals cell heterogeneity and transcriptome profile of breast cancer lymph node metastasis	83
Lipids in cancer: a global view of the contribution of lipid pathways to metastatic formation and treatment resistance	70
Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia	70
TGF-β1-mediated transition of resident fibroblasts to cancer-associated fibroblasts promotes cancer metastasis in gastrointestinal stromal tumor	60
Metformin exhibits antiproliferation activity in breast cancer via miR-483-3p/METTL3/m6A/p21 pathway	53
miR-18a promotes glioblastoma development by down-regulating ALOXE3-mediated ferroptotic and anti-migration activities	52
RETRACTED ARTICLE: PI3K/Akt pathway and Nanog maintain cancer stem cells in sarcomas	47
IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming	43
LONP1 and ClpP cooperatively regulate mitochondrial proteostasis for cancer cell survival	39
Diethyldithiocarbamate-copper complex (CuET) inhibits colorectal cancer progression via miR-16-5p and 15b-5p/ALDH1A3/PKM2 axis-mediated aerobic glycolysis pathway	38
Triptolide targets super-enhancer networks in pancreatic cancer cells and cancer-associated fibroblasts	38
USP29-mediated HIF1α stabilization is associated with Sorafenib resistance of hepatocellular carcinoma cells by upregulating glycolysis	37
YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells	34
Dissecting the single-cell transcriptome network in patients with esophageal squamous cell carcinoma receiving operative paclitaxel plus platinum chemotherapy	32
Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells	32
Breast cancer in the era of integrating “Omics” approaches	30
Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy	29
Epigenetic regulation of TGF-β-induced EMT by JMJD3/KDM6B histone H3K27 demethylase	29
Angiogenesis and immune checkpoint dual blockade in combination with radiotherapy for treatment of solid cancers: opportunities and challenges	28
OXER1 and RACK1-associated pathway: a promising drug target for breast cancer progression	27
Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers	27
Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: a promising target in anti-cancer therapies	27
Tumour heterogeneity and evolutionary dynamics in colorectal cancer	26

Tumor-secreted exosomal Wnt2B activates fibroblasts to promote cervical cancer progression	26
Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis	25
EHF suppresses cancer progression by inhibiting ETS1-mediated ZEB expression	24
TRPC1 promotes the genesis and progression of colorectal cancer via activating CaM-mediated PI3K/AKT signaling axis	24
Hypoxia promotes an inflammatory phenotype of fibroblasts in pancreatic cancer	23
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment	23
Inactivation of the CIC-DUX4 oncogene through P300/CBP inhibition, a therapeutic approach for CIC-DUX4 sarcoma	22
Emerging role of G9a in cancer stemness and promises as a therapeutic target	22
MiR-22, regulated by MeCP2, suppresses gastric cancer cell proliferation by inducing a deficiency in endogenous S-adenosylmethionine	22
Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma	21
Fatty acid transport protein-5 (FATP5) deficiency enhances hepatocellular carcinoma progression and metastasis by reprogramming cellular energy metabolism and regulating the AMPK-mTOR signaling pathwa	20
Inhibition of Bruton’s tyrosine kinase as a therapeutic strategy for chemoresistant oral squamous cell carcinoma and potential suppression of cancer stemness	20
PRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1	20
Non-metabolic role of UCK2 links EGFR-AKT pathway activation to metastasis enhancement in hepatocellular carcinoma	20
Tumour cells express functional lymphatic endothelium-specific hyaluronan receptor in vitro and in vivo: Lymphatic mimicry promotes oral oncogenesis?	20
Elevated ATGL in colon cancer cells and cancer stem cells promotes metabolic and tumorigenic reprogramming reinforced by obesity	20
Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC)	20
SIAH1 reverses chemoresistance in epithelial ovarian cancer via ubiquitination of YBX-1	19
The mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance	19
PBK phosphorylates MSL1 to elicit epigenetic modulation of CD276 in nasopharyngeal carcinoma	19
E2F1 and epigenetic modifiers orchestrate breast cancer progression by regulating oxygen-dependent ESRP1 expression	18
NNMT promotes the progression of intrahepatic cholangiocarcinoma by regulating aerobic glycolysis via the EGFR-STAT3 axis	18
A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo	17
Disruption of STAT5A and NMI signaling axis leads to ISG20-driven metastatic mammary tumors	17
Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4	17
Estradiol-mediated inhibition of DNMT1 decreases p53 expression to induce M2-macrophage polarization in lung cancer progression	17
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression	17
Heterogeneity of subsets in glioblastoma mediated by Smad3 palmitoylation	17
Sulfated alginate oligosaccharide exerts antitumor activity and autophagy induction by inactivating MEK1/ERK/mTOR signaling in a KSR1-dependent manner in osteosarcoma	17
PSMC2 promotes the progression of gastric cancer via induction of RPS15A/mTOR pathway	16
EZH2 facilitates BMI1-dependent hepatocarcinogenesis through epigenetically silencing microRNA-200c	16
The E3 ubiquitin ligase MG53 inhibits hepatocellular carcinoma by targeting RAC1 signaling	15
Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma	15
CCT8 recovers WTp53-suppressed cell cycle evolution and EMT to promote colorectal cancer progression	15
YWHAE-NUTM2 oncoprotein regulates proliferation and cyclin D1 via RAF/MAPK and Hippo pathways	15
TGFβ/cyclin D1/Smad-mediated inhibition of BMP4 promotes breast cancer stem cell self-renewal activity	15
Connexin 43 confers chemoresistance through activating PI3K	15
C20orf204, a hepatocellular carcinoma-specific protein interacts with nucleolin and promotes cell proliferation	15
Precision modeling of gall bladder cancer patients in mice based on orthotopic implantation of organoid-derived tumor buds	14
UHRF1 overexpression promotes osteosarcoma metastasis through altered exosome production and AMPK/SEMA3E suppression	14
Kras activation in endometrial organoids drives cellular transformation and epithelial-mesenchymal transition	14
The prohibitin-binding compound fluorizoline inhibits mitophagy in cancer cells	14
Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis	14
USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancer	14